PRLog - April 30, 2014 - LONDON -- Dr George Badescu, Director of Scientific Affairs – Bioconjugation & Protein Engineering, from PolyTherics UK, was asked a few questions about the ADC conference taking place on 19th and 20th May and about the industry. He will be providing this year's attendees with unique insights on ThioBridge Conjugation with a focus on novel ADC formats, site specific conjugation, payloads, mAb and Fab conjugates.
ADC Summit | 19-20 May, London UK
"The agenda and faculty of speakers are both very impressive. The talks cover all the relevant aspects of the ADCs and there are a few talks bringing all the separate elements together and putting everything in perspective"
He highlighted the Genentech presentation on toxicity strategies, the Medimmune address on target selection, and the Pfizer keynote entitled: Design and Development of Effective ADCs - Putting the Pieces Together, as being some of the most interesting sessions this year.
When asked what he believed to be the biggest challenges for the pharmaceutical industry regarding ADC’s, Dr Badescu said:
“ADCs have very complex requirements for conditional stability – they have to be stable in circulation during their journey to the target but have to become very unstable when they reach the target to release the payload.”
“Only a very small fraction of the injected dose ever reaches the tumour, the vast majority of the administered ADC is metabolised by non-target healthy cells and tissues”
“Very little about ADCs can be predicted – ADC development and optimisation remains very empirical with an enormous number of variables that are difficult to control and isolate. The best combinations of targets, antibodies, linkers and payloads are difficult to identify”
“Tumours are very heterogeneous and they evolve – spatial and temporal heterogeneity. ADCs are multi-component molecules and the separate components are usually developed / owned by different organisations. Commercially, it may be difficult to bring all the components together.”
The full interview is available in the event download centre at http://www.smi-
The 3rd annual ADC agenda will feature an expert and highly accredited speaker line up who will spotlight on topical areas such as nanotechnology, ADC manufacturing, pre-clinical development, payload/linker strategies, safety and the future of ADCs.
Some of the confirmed attendees include:
Ablynx, ADC Therapeutics Services, Algeta AS, Carbogen AMCIS, ImmunoGen, Inc, Imperial College London, LGC, Medimmune Inc, Merck, Mersana Therapeutics, Peakdale Molecular, Philochem, Photobiotics, Progenics Pharmaceuticals, Regeneron, SafeBridge Europe, Sanofi, Spirogen, Sutro Biopharma, Synaffix, Synthon, Takeda, University College London, University of Oxford, Viventia
Further information including the conference brochure, short interviews and registration details are available at http://www.smi-
ADC SUMMIT 2014
19TH AND 20TH MAY
Holiday Inn Kensington Forum, London UK
Sponsored by PolyTherics, Synaffix and Viventia Bio Inc
About SMi Group
Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-
We pride ourselves on having access to the worlds most forward thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. We hold events in over 30 major cities throughout the world including London, Paris and Singapore and to date have welcomed over 200,000 participants from 80 countries.
More information can be found at www.smi-online.co.uk